Spondyloarthritis & psoriatic arthritis
Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics
Authors' conclusion
The risk of developing PsA appeared slightly different in patients receiving diverse classes of biologics.
Study context
- Population
- Consecutive bionaïve plaque psoriasis patients starting biologic treatment
- Participants
- 622 patients2,510 person-years
- Exposure
- IL-17 and IL-23 inhibitors vs TNF inhibitors
- TNFn = 317reference
- IL-17n = 164
- IL-23n = 141
- Outcome
- Incident PsA
Methodological detailsInverse probability of treatment weighting (IPTW) in the setting of multiple treatments, IPTW Cox regression
- IPTW in the setting of multiple treatments
- IPTW Cox regression
Main finding
As reported in the abstract
during the observation period
Each group vs TNFHazard ratio (95% CI)
IL-17
0.63(0.38–1.05)
IL-23
0.57(0.34–0.96)
Observational data: associations, not effects.
Original publication
Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics. Ann Rheum Dis. Published 6 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →